Astral Systems Raises £23M Series A for Fusion Medical Isotopes

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Astral Systems, a deep tech company based in Bristol, England, has raised £23 million in Series A funding to scale fusion reactors that produce medical isotopes used in cancer diagnosis and treatment. The round was led by Mercia Ventures.

What sets Astral apart from much of the fusion field is that it is already running reactors rather than working toward distant power generation. The company has generated more than £3 million in revenue from research contracts, a rare position in an industry where most players are years away from commercial output.

The investment also drew support from Tees River, Daphni, and Blast Club, alongside earlier backers Speedinvest and Playfair.

Astral plans to run several next-generation reactors at full capacity by the end of 2026 at its new site at the former Berkeley Power Station in Gloucestershire. That location is a decommissioned nuclear site that already has grid connections, nuclear-grade infrastructure, and an established relationship with the Office for Nuclear Regulation. The company is aiming to reach profitability during 2027 and to grow its team from 23 people to more than 40 by the end of 2026.

The raise stands out in a sector usually defined by long timelines, with Astral positioning medical isotope production as a near-term commercial use of fusion technology.